BioCentury
ARTICLE | Clinical News

Pfizer eyes submission after TTR readout

August 31, 2018 6:47 PM UTC

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality.

Pfizer has identified tafamidis, a small molecule that stabilizes the TTR protein and prevents its misfolding, as a potential blockbuster drug. The company told BioCentury that it plans to submit an NDA to FDA by year end for tafamidis to treat TTR amyloid cardiomyopathy...

BCIQ Company Profiles

Pfizer Inc.

BCIQ Target Profiles

Transthyretin (TTR)